The proinflammatory transcription factor NF-κB regulates more than 500 different genes expressing for proteins involved in cellular signaling pathways, so all compounds that interact with NF-κB, inhibiting it, may be used in cancer therapy. This evidence concerns the gene NFKB1 and cancer.